{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:03:43Z","timestamp":1790633023382,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104821","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:41:02Z","timestamp":1781800862000},"page":"104821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0358-6652","authenticated-orcid":false,"given":"Maria Inez","family":"Dacoregio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio Ernesto do","family":"Rego Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7154-8692","authenticated-orcid":false,"given":"Isadora","family":"Mamede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1678-3142","authenticated-orcid":false,"given":"Cain\u00e3 Gon\u00e7alves","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Thimotheo Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-0403","authenticated-orcid":false,"given":"Isabella","family":"Michelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Zattar","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Reinaldo de","family":"Oliveira Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Colombo","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysa","family":"Vilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-3234","authenticated-orcid":false,"given":"Ricardo Lima","family":"Barros Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104821_bib1","first-page":"105","article-title":"Cardiac toxicity in patients receiving anthracycline- and trastuzumab-based regimens for early-stage breast cancer","volume":"18","author":"Smith","year":"2022","journal-title":"Cardiol Toxicol"},{"key":"10.1016\/j.breast.2026.104821_bib2","article-title":"Managing short- and long-term toxicity of chemotherapy in early breast cancer: focus on peripheral neuropathy and cardiotoxicity","volume":"50","author":"Daugaard","year":"2021","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.breast.2026.104821_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.breast.2026.104821_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.breast.2026.104821_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104821_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab vs docetaxel in advanced NSCLC","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104821_bib7","first-page":"253","article-title":"Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense doxorubicin and cyclophosphamide: no evidence for inferior outcomes among African-American and Hispanic women in CALGB 40603","volume":"160","author":"Sikov","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104821_bib8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2112651","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104821_bib9","first-page":"123","article-title":"Event-free and overall survival with neoadjuvant\u2013adjuvant pembrolizumab in triple-negative breast cancer","volume":"390","author":"Schmid","year":"2024","journal-title":"NEJM"},{"key":"10.1016\/j.breast.2026.104821_bib10","first-page":"50","article-title":"Atezolizumab plus neoadjuvant nab-paclitaxel and anthracycline-based chemotherapy in early TNBC (IMpassion031)","volume":"23","author":"Schmid","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104821_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104821_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.breast.2026.104821_bib14","first-page":"1","article-title":"Adverse events and tolerability of immune checkpoint inhibitors (ICI) for the treatment of early-stage breast cancer (BC)","author":"Inez Dacoregio","year":"2024","journal-title":"PROSPERO"},{"key":"10.1016\/j.breast.2026.104821_bib15","series-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","year":"2017"},{"key":"10.1016\/j.breast.2026.104821_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.breast.2026.104821_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"Br Med J"},{"issue":"7109","key":"10.1016\/j.breast.2026.104821_bib18","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.breast.2026.104821_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.breast.2026.104821_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"issue":"Suppl 5","key":"10.1016\/j.breast.2026.104821_bib21","first-page":"v851","article-title":"Neoadjuvant durvalumab plus chemotherapy in early triple-negative breast cancer (GeparNuevo phase II): safety and efficacy analysis","volume":"30","author":"Mittendorf","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2112651","article-title":"Pembrolizumab for early triple-negative breast cancer (KEYNOTE-522): overall survival and safety outcomes","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.breast.2026.104821_bib23","first-page":"1006","article-title":"Adaptive randomization of an immune checkpoint inhibitor in I-SPY2 breast cancer trial: safety and efficacy insights","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.breast.2026.104821_bib24","first-page":"504","article-title":"Neoadjuvant PD-L1 checkpoint inhibition (NeoTRIP trial) in early breast cancer: toxicity and response rates","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104821_bib25","first-page":"768","article-title":"IMpassion050: safety analysis of atezolizumab in HER2+ early-stage breast cancer","volume":"33","author":"Hurvitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.breast.2026.104821_bib26","first-page":"S298","article-title":"KEYNOTE-756: pembrolizumab plus chemotherapy in early breast cancer\u2014safety and tolerability data","volume":"34","author":"Harbeck","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl_14","key":"10.1016\/j.breast.2026.104821_bib27","article-title":"CheckMate-7FL: nivolumab with endocrine therapy in hormone receptor\u2013positive early breast cancer\u2014safety results","volume":"83","author":"Fasching","year":"2023","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2026.104821_bib28","first-page":"750","article-title":"APTneo: pembrolizumab in HER2- early breast cancer\u2014clinical safety outcomes","volume":"8","author":"Parker","year":"2022","journal-title":"JAMA Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.breast.2026.104821_bib29","first-page":"S420","article-title":"NeoTENNIS: durvalumab in neoadjuvant TNBC\u2014Toxicity profile","volume":"33","author":"Bianchini","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib30","first-page":"601","article-title":"neoTAPPL: phase I study of tremelimumab in early breast cancer\u2014safety outcomes","volume":"188","author":"Morales-V\u00e1squez","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"10.1016\/j.breast.2026.104821_bib31","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1200\/JCO.24.00003","article-title":"PEARL: a phase Ib\/II biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2\u2013Negative breast cancer","volume":"42","author":"Ho","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib32","doi-asserted-by":"crossref","unstructured":"Nederlof, I. et al. LBA11 neoadjuvant nivolumab\/relatlimab or nivolumab\/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs) . Ann Oncol, Volume 35, S1206..","DOI":"10.1016\/j.annonc.2024.08.2249"},{"issue":"5","key":"10.1016\/j.breast.2026.104821_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2026.104821_bib34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy (FACT) scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104821_bib35","first-page":"894","article-title":"The PROMIS wave 1 pilot study in a population-based sample","volume":"51","author":"Cushman","year":"2013","journal-title":"Med Care"},{"key":"10.1016\/j.breast.2026.104821_bib36","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104821_bib38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab versus dacarbazine in untreated metastatic melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104821_bib39","first-page":"994","article-title":"IMpassion130: atezolizumab + nab-paclitaxel in metastatic TNBC","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib40","first-page":"12","article-title":"Recommendations for the use of pharmacogenetics in anticancer drugs: 2021 update from the French national network","volume":"157","author":"Loriot","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104821_bib41","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.csbj.2019.03.006","article-title":"Application of PD-1 blockade in cancer immunotherapy","volume":"17","author":"Wu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"10.1016\/j.breast.2026.104821_bib42","first-page":"e263","article-title":"Immune-mediated AEs","volume":"23","author":"Ramos-Casals","year":"2022","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.breast.2026.104821_bib43","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104821_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104473","article-title":"Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real\/GBECAM 0123 study","volume":"83","author":"Andrade","year":"2025","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.breast.2026.104821_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2026.104821_bib46","first-page":"2185","article-title":"Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma [published correction appears in","volume":"379","author":"Larkin","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2026.104821_bib47","article-title":"Hepatotoxicity with checkpoint inhibitors","volume":"17","author":"Wang","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.breast.2026.104821_bib48","first-page":"1","article-title":"Immune-related AEs of checkpoint inhibitors: meta-analysis","volume":"1","author":"Petrelli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1539246","key":"10.1016\/j.breast.2026.104821_bib49","article-title":"Safety of immunotherapy: meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.breast.2026.104821_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.breast.2026.104821_bib51","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.breast.2026.104821_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1190001","article-title":"Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis","volume":"14","author":"Lin","year":"2023","journal-title":"Front Pharmacol"},{"issue":"384","key":"10.1016\/j.breast.2026.104821_bib53","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic TNBC","volume":"16","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.breast.2026.104821_bib54","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor\u2013induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104821_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor\u2013associated cardiovascular toxic effects: international cardio-oncology society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104821_bib56","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","article-title":"Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study","volume":"47","author":"Salem","year":"2026","journal-title":"Eur Heart J"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:28:12Z","timestamp":1784928492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"alternative-id":["S0960977626001311"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104821","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity profile and tolerability of immune checkpoint inhibitors for the treatment of early-stage breast cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104821"}}